Invention Grant
- Patent Title: Polypeptides, cells, and methods involving engineered CD16
-
Application No.: US17233979Application Date: 2021-04-19
-
Publication No.: US11370825B2Publication Date: 2022-06-28
- Inventor: Bruce Kenneth Walcheck , Dan Samuel Kaufman , Jianming Wu , Yawu Jing , Zhenya Ni
- Applicant: Regents of the University of Minnesota
- Applicant Address: US MN Minneapolis
- Assignee: Regents of the University of Minnesota
- Current Assignee: Regents of the University of Minnesota
- Current Assignee Address: US MN Minneapolis
- Agency: Fish & Richardson P.C.
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12N15/63 ; C07K17/00 ; A61K48/00 ; C07K14/735 ; C12N5/0783 ; A61K35/17 ; A61K38/17 ; A61K39/395 ; C07K16/32 ; C12N5/0787 ; C12N5/0786 ; A01K67/00 ; A61K39/00
Abstract:
This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
Public/Granted literature
- US20210332103A1 POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16 Public/Granted day:2021-10-28
Information query
